The Effect of Acuity Circles on Deceased Donor Transplant and Offer Rates Across Model for End‐Stage Liver Disease Scores and Exception Statuses

Andrew Wey, Samantha Noreen, Sommer Gentry, Matt Cafarella, James Trotter, Nicholas Salkowski, Dorry L. Segev, Ajay Israni, Bertram Kasiske, Ryutaro Hirose, Jon Snyder – 4 September 2021 – Acuity circles (AC), the new liver allocation system, was implemented on February 4, 2020. Difference‐in‐differences analyses estimated the effect of AC on adjusted deceased donor transplant and offer rates across Pediatric End‐Stage Liver Disease (PELD) and Model for End‐Stage Liver Disease (MELD) categories and types of exception statuses.

Comprehensive characterization of viral integrations and genomic aberrations in HBV‐infected intrahepatic cholangiocarcinomas

Jihyun An, Deokhoon Kim, Bora Oh, Yoo‐Jin Oh, Jihyun Song, Naomi Park, Ha Il Kim, Hyo Jeong Kang, Ji‐Hye Oh, Wonkyung Kim, Eunjung Lee, Chang Ohk Sung, Gi‐Won Song, Dae‐Ghon Kim, Eunsil Yu, Eric Letouzé, Jessica Zucman‐Rossi, Han Chu Lee, Ju Hyun Shim – 2 September 2021

LiverLearning®: 2021 Webinar: Biliary Atresia: Where We Are and Where Do We Go from Here?

Biliary atresia (BA) is a rapidly progressive inflammatory fibro-obliterative process affecting intra and extra hepatic bile ducts. BA is the most common indication for liver transplantation in children, however the etiopathogenesis is not completely understood. This one hour webinar will summarize genomics in BA, current diagnostic algorithms and novel prognosticators for BA, and long term outcomes of BA. Learners will gain understanding of current practices and future directions in etiopathogenesis and outcomes of BA.Kathleen M. Loomes Kathleen M.

Quantification of polyreactive immunoglobulin G facilitates the diagnosis of autoimmune hepatitis

Richard Taubert, Bastian Engel, Jana Diestelhorst, Katharina L. Hupa‐Breier, Patrick Behrendt, Niklas T. Baerlecken, Kurt‐Wolfram Sühs, Maciej K. Janik, Kalliopi Zachou, Marcial Sebode, Christoph Schramm, María‐Carlota Londoño, Sarah Habes, the UK‐AIH Consortium, Ye H. Oo, Claudine Lalanne, Simon Pape, Maren Schubert, Michael Hust, Stefan Dübel, Mario Thevis, Danny Jonigk, Julia Beimdiek, Falk F. R. Buettner, Joost P. H. Drenth, Luigi Muratori, David H. Adams, Jessica K. Dyson, Amédée Renand, Isabel Graupera, Ansgar W. Lohse, George N.

Risk of Cardiovascular Disease in Individuals With Nonobese Nonalcoholic Fatty Liver Disease

Ashwini Arvind, Jacqueline B. Henson, Stephanie A. Osganian, Cheryl Nath, Lara M. Steinhagen, Zoe N. Memel, Arley Donovan, Oluwafemi Balogun, Raymond T. Chung, Tracey G. Simon, Kathleen E. Corey – 1 September 2021 – Nonalcoholic fatty liver disease (NAFLD) is independently associated with obesity and cardiovascular disease (CVD). CVD is the primary cause of mortality in the predominantly obese population of adults with NAFLD.

Subscribe to